Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6251559 | 1.00 | PARP1 (0.33) | PARP1CA1CA2IDO1ANPEP | |
| SCHEMBL19151732 | 0.81 | PARP1 (0.33) | PARP1CA1CA2IDO1 | |
| SCHEMBL2524855 | 0.74 | PARP1 (0.36) | PARP1CA1CA2IDO1ANPEP | |
| SCHEMBL18026599 | 0.69 | PARP1 (0.36) | PARP1CA1CA2IDO1 | |
| SCHEMBL4824305 | 0.69 | IDO1 (0.40) | PARP1CA1CA2IDO1ANPEP | |
| SCHEMBL15233622 | 0.69 | PARP1 (0.36) | PARP1CA1CA2IDO1ANPEP | |
| SCHEMBL30317868 | 0.69 | CYP19A1 (0.37) | PARP1IDO1 | |
| SCHEMBL225642 | 0.69 | PARP1 (0.36) | PARP1CA1CA2IDO1 | |
| SCHEMBL8161816 | 0.69 | CYP19A1 (0.37) | PARP1IDO1 | |
| SCHEMBL29769887 | 0.69 | IDO1 (0.40) | PARP1CA1CA2IDO1ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315551-A1 | 2-ALKYLCARBONYL[2,3-b]FURAN-4,9-DIONE PRODUCTION METHOD AND PRODUCTION INTERMEDIATE THEREFOR | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315551-A1 | 2-ALKYLCARBONYL[2,3-b]FURAN-4,9-DIONE PRODUCTION METHOD AND PRODUCTION INTERMEDIATE THEREFOR | WEE2, DHPS, WEE1 | PARP1 702/4885CA1 2509/4885CA2 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.